She has tested the preventative potential of pharmacologic treatment with perindopril on new onset chronic disease in currently unaffected people, showing a possible protective effect in women. She showed that screening and treatment of preterminal kidney disease in remote-living Australian Aboriginal reduces dialysis needs, deaths and costs that work has helped transform Australian Aboriginal health services, and underpins many screening and treatment programs globally. She was the first to demonstrate the contribution of low birthweight to kidney disease in Australia, manifest in remote living Australian Aborigines, and then drove demonstrations of birthweight’s effects on health profiles in mainstream Australians through the AUSDIAB study. She promotes an integrated view of non-communicable chronic diseases, and interpretation of health profiles in multi-determinant frameworks. She was among the first to describe kidney disease, independent of diabetes, in Native Americans, in studies of Zuni, Rio Grande Pueblo, Navajo and Apache Indians in the Southwest of the USA. She is recognised internationally for her multidisciplinary research into kidney and related chronic disease, particularly in high-risk populations. Finally, she established the Native American Renal Disease Research Program through which her early studies of kidney and related chronic disease in American Indians were conducted. She was Deputy Medical Director of the Lovelace-based, CDC sponsored, clinical examination component of the Veterans’ Health Study of Agent Orange (Dioxin Toxicity), and was for several months the Medical Director of the clinical examination component of the study of instrustrial dioxin toxicity sponsored by NIOSH. She pioneered the development and application of a clinical/epidemiologic database from adminstrative datasets of the affiliated Lovelace Medical Centre and Health Maintenance Organisation, which became embedded practice in all major heath care institutions. She worked for 20 years in the USA, in academic and clinical nephrology, kidney transplantation, and clinical trials, and developed a very successful Clinical Trials Unit at the Lovelace Medical Foundation (LMF) in Albuquerque, New Mexico. She trained in Medicine and Nephrology in the USA and is board certified in Medicine and Nephrology in the USA and Australia. She graduated from Sydney University with BMedcSci in Immunology (HI) in 1967, and MB BS (H1) in 1969.
She graduated from Telopea Park High School in Canberra, with the top Leaving Certificate score among students (>27,000) in New South Wales and the Australian Capital Territory. Her work has been recognised through the International Distinguished Medal of the National Kidney Foundation in the USA in 2008, the Australian Research Fellowship: National Health and Medical Research Council, 2008-2012, appointment as ” Officer of the Order of Australia (AO) by the Commonwealth of Australia in 2010 and election as a Fellow of the Australian Academy of Science (FAA) in 2015. She is recognised internationally for her multidisciplinary research and policy and program development in kidney and related chronic disease, particularly in high-risk populations. Professor Wendy Hoy is Professor of Medicine and Director of the Centre for Chronic Disease at the University of Queensland in Australia.
0 kommentar(er)
